Last reviewed · How we verify
Ferric Carboxymaltose Injection [Injectafer®]
Ferric Carboxymaltose Injection [Injectafer®], marketed by Sichuan Huiyu Pharmaceutical Co., Ltd, is an iron replacement therapy with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and mechanism of action, which supports its use in treating iron deficiency anemia. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Ferric Carboxymaltose Injection [Injectafer®] |
|---|---|
| Also known as | Ferinject |
| Sponsor | Sichuan Huiyu Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: